Products
Data
Feature
Plans
Request Demo
Sign Up for Free
Blog
Valuable Targets
Advanced Tech.
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Oloctinebart Biologics Sequence Review Report 2026: LGALS3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Oloctinebart, an antibody targeting LGALS3.
Read →
Latest Hotspot
8 min read
Lunaxafusp Biologics Sequence Review Report 2026: HER2 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lunaxafusp, an antibody targeting HER2.
Read →
Latest Hotspot
8 min read
Eglatoprutug Biologics Sequence Review Report 2026: KIT Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eglatoprutug, an antibody targeting KIT.
Read →
Latest Hotspot
8 min read
Zeleciment Biologics Sequence Review Report 2026: TFRC Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zeleciment, an antibody targeting TFRC.
Read →
Latest Hotspot
8 min read
Vixticibart Biologics Sequence Review Report 2026: NPR1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vixticibart, an antibody targeting NPR1.
Read →
Latest Hotspot
8 min read
Usilnetug Biologics Sequence Review Report 2026: APP Aβ N3pGlu Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Usilnetug, an antibody targeting APP Aβ N3pGlu.
Read →
Latest Hotspot
8 min read
Trosunilimab Biologics Sequence Review Report 2026: ITGA4B7 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Trosunilimab, an antibody targeting ITGA4B7.
Read →
Latest Hotspot
8 min read
Timcevibart Biologics Sequence Review Report 2026: SARS-CoV-2 Spike RBD Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Timcevibart, an antibody targeting SARS-CoV-2 Spike RBD.
Read →
Latest Hotspot
8 min read
Pegrizeprument Biologics Sequence Review Report 2026: CD28 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pegrizeprument, an antibody targeting CD28.
Read →
Latest Hotspot
8 min read
Olintatug Biologics Sequence Review Report 2026: KAAG1 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Olintatug, an antibody targeting KAAG1.
Read →
Latest Hotspot
8 min read
Avitotamig Biologics Sequence Review Report 2026: SIGLEC3 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Avitotamig, an antibody targeting SIGLEC3.
Read →
Latest Hotspot
8 min read
Rilogrotug Biologics Sequence Review Report 2026: GDF15 Similarity and Patent-Risk Signals
27 July 2026
Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rilogrotug, an antibody targeting GDF15.
Read →
<
1
<<
1849
1850
1851
1852
1853
>>
2926
>